CEO Stanley Erck told BioWorld Today that Novavax Inc. is shifting focus to generate "much more broadly neutralizing antibodies which should – we have to demonstrate this in humans – make for a better flu vaccine," as the firm sets aside its virus-like particle (VLP)-based seasonal influenza candidate in favor of pursuing a nanoparticle-based prospect.